CEO Glenn A. Oclassen to Join Sleep Experts in Panel Hosted by Natixis
PT. RICHMOND, Calif., Oct. 1 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, President and Chief Executive Officer, will participate in a panel focused on middle-of-the-night (MOTN) insomnia at the Natixis Bleichroeder "Hidden Gems" Healthcare Conference.
Date: Monday, October 8, 2007
Panel Discussion: 3:45 p.m. ET
Company Presentation: 4:45 p.m. ET
Location: The Carlton Hotel at 88 Madison Avenue, New York, NY
Mr. Oclassen commented, "This is the first panel sponsored by the investment community to discuss the form of insomnia that is characterized by patients who awaken in the middle of the night and have difficulty returning to sleep. According to a recent survey conducted by the Stanford Sleep Epidemiology Research Center, it is estimated that up to 35% of Americans over the age of 18 suffer primarily from this and related forms of sleep disorder. Despite this large patient population, there is no pharmaceutical agent currently approved to treat this common sleep problem."
"Transcept is developing Intermezzo(TM) (zolpidem tartrate lozenge) for the treatment of such MOTN insomnia. In a recently completed Phase 3 sleep laboratory study, Intermezzo(TM) met the primary endpoint of decreasing sleep onset after a middle of the night awakening, without next day residual effects. I look forward to participating in this panel with these respected sleep experts and raising awareness of this aspect of insomnia."
The MOTN insomnia panel will be co-hosted by Corey Davis, Ph.D., and Jon LeCroy, M.D. of Natixis Bleichroeder. The panel of sleep experts will include Martin B. Scharf, PhD, Director, Center for Research in Sleep Disorders, Cincinnati, Ohio and Gary K. Zammit, Ph.D., Director of the Sleep Disorders Institute at St. Luke's/Roosevelt Hospital, NYC.
Dr. Davis commented, "The potential for the novel claim for MOTN dosing could reduce some of the lingering stigma attached to taking a sleep medication, and perhaps help accelerate growth in the prescription market to a level more consistent with the historical and emerging epidemiological studies that suggest a high prevalence of MOTN insomnia in the US population."
Intermezzo(TM) (zolpidem tartrate lozenge) is a low dose formulation of zolpidem that is currently in late phase 3 clinical trials for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Formulated as a sublingual tablet that dissolves under the tongue, Intermezzo(TM) employs Transcept's Bimucoral(TM) technology to accelerate bioavailability. The company intends to file the Intermezzo(TM) NDA with the US Food and Drug Administration (FDA) in 2008.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product, Intermezzo(TM) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem that is currently in late phase 3 clinical trials for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Another product being developed by Transcept is TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. TO-2060 is currently the subject of an initial proof of concept trial in the treatment of alcohol use disorder. For more information, please visit the Company's website at: http://www.transcept.com.
|SOURCE Transcept Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved